Study of Semaglutide Effects on Brain Insulin Response in Adults with Normal Weight, Overweight, or Obesity

What this Trial Is About

Researchers are evaluating the effects of a GLP-1 receptor agonist called semaglutide on brain insulin responsiveness in healthy adults with normal weight, overweight, or obesity. This randomized, single-blinded, crossover study compares semaglutide with a placebo to understand how these treatments affect brain responses to insulin. The main goal is to observe changes in cerebral blood flow and brain activity related to insulin using functional MRI imaging. Participants receive an acute dose of 0.25 mg semaglutide or a saline placebo by subcutaneous injection. After 24 hours, they undergo functional MRI scans paired with intranasal insulin or placebo administration. The study also assesses cognitive function and eating behavior during these visits. The trial includes both male and female adults aged 18 to 70 and allows participants to serve as their own controls by crossing over between treatments. Throughout the study, participants complete brain imaging sessions, cognitive tests, and questionnaires about hunger, food cravings, and mood. Researchers measure brain responses to insulin, neural reactions to food cues, heart rate variability, and diffusion-weighted imaging changes. Safety and health are monitored, including screening for infections, recent surgeries, and medication use. The study aims to provide insights into brain insulin sensitivity influenced by GLP-1 receptor activation over the trial period.

Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness